MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$5,141,417
Unit: Dollar
Positive Cash Flow Breakdown
Preferred stock offering
Shares issued for cash
Shares issued for non-employee s...
Others
Negative Cash Flow Breakdown
Net loss
Non-cash revenue
Change in fair value of derivati...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-12-31
Net loss
-12,277,192
Depreciation and amortization
1,181,212
Right of use asset amortization
41,385
Amortization of debt discount
545,635
Non-cash revenue
1,333,045
Stock based compensation
1,215,692
Shares issued for non-employee services
3,829,220
Warrants issued for services
824,295
Change in fair value of derivative liability
906,430
Change in fair value of derivative liability warrants
-191,625
Loss on shares issued for conversion of debt
0
(gain) loss on extinguishment of debt
159,035
Forgiveness of interest
0
Unrealized loss on investments
-163,500
Unrealized gain on marketable securities
76,596
Interest receivable
7,348
Prepaid assets
473,497
Accounts payable
-381,012
Accrued expenses
-440,889
Right of use liability
-42,306
Other current liabilities
-115,000
Net cash used in operating activities
-8,603,036
Net cash used in investing activities
0
Proceeds from notes payable
990,000
Repayment of notes payable
-218,750
Shares issued for sepa
2,958,848
Shares issued for cash
4,558,455
Warrants issued for cash
0
Pre-funded warrants exercise
900
Preferred stock offering
5,455,000
Net cash provided by financing activities
13,744,453
Net increase (decrease) in cash
5,141,417
Cash at beginning of period
532,885
Cash at end of period
5,674,302
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Preferred stock offering
$5,455,000
Shares issued for cash
$4,558,455
Shares issued for sepa
$2,958,848
Proceeds from notes
payable
$990,000
Pre-funded warrants
exercise
$900
Net cash provided by
financing activities
$13,744,453
Canceled cashflow
$218,750
Net increase
(decrease) in cash
$5,141,417
Canceled cashflow
$8,603,036
Repayment of notes payable
-$218,750
Shares issued for
non-employee services
$3,829,220
Stock based
compensation
$1,215,692
Depreciation and
amortization
$1,181,212
Warrants issued for
services
$824,295
Amortization of debt discount
$545,635
Unrealized loss on
investments
-$163,500
Right of use asset
amortization
$41,385
Net cash used in
operating activities
-$8,603,036
Canceled cashflow
$7,800,939
Net loss
-$12,277,192
Non-cash revenue
$1,333,045
Change in fair value of
derivative liability
$906,430
Prepaid assets
$473,497
Accrued expenses
-$440,889
Accounts payable
-$381,012
Change in fair value of
derivative liability...
-$191,625
(gain) loss on
extinguishment of debt
$159,035
Other current
liabilities
-$115,000
Unrealized gain on
marketable securities
$76,596
Right of use liability
-$42,306
Interest receivable
$7,348
Buy us a coffee
Coeptis Therapeutics Holdings, Inc. (COEP)
Coeptis Therapeutics Holdings, Inc. (COEP)